Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

The active ingredient consists of a de‑O‑acetylated polysaccharide from N. meningitidis group C chemically linked to tetanus toxoid. This conjugation creates a T‑cell‑dependent antigen that elicits a strong IgG antibody response and immunologic memory, thereby providing active protection against future exposure to serogroup C meningococci.

The dosing regimen for Neisvac-C is determined by the prescribing healthcare professional based on the patient’s age, risk factors and local immunization guidelines. The prescriber will specify the number of doses, interval between doses and any booster requirements.

Safety data for Neisvac-C in pregnancy are limited, so it should be used only when the potential benefit justifies any possible risk to the fetus. There is no specific contraindication for breastfeeding, but the decision should be made in consultation with a qualified health professional.

To place an order, submit an enquiry on the Neisvac-C product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac-C is a serogroup‑specific conjugate vaccine targeting only N. meningitidis group C, whereas broader vaccines such as Menactra or Menveo protect against multiple serogroups (A, C, W, Y). The conjugate technology in Neisvac-C provides a T‑cell‑dependent response, which generally yields longer‑lasting immunity compared with plain polysaccharide vaccines.

Neisvac-C must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the cold chain is broken, discard the product according to local regulations.

Neisvac-C is supplied as an injectable solution for intramuscular injection, typically into the deltoid muscle of the upper arm. The administration is performed by a qualified healthcare professional using aseptic technique.

The most serious adverse events reported with Neisvac-C include anaphylaxis, severe allergic reactions, Guillain‑Barré syndrome, and rare neurologic complications such as seizures. Immediate medical attention is required if any of these symptoms develop after vaccination.

Neisvac-C should not be given to individuals with a documented severe allergy to any component of the vaccine or to those who have experienced a previous anaphylactic reaction to a dose of the same vaccine. It is also contraindicated in persons for whom the product label specifies age restrictions.